|
Exploration for Chemical Filter Cartridges that Can Reduce Nitrogen Oxides, a Common Factor in the Formation of Nitrosamines
|
|
0
|
115
|
December 15, 2024
|
|
How to decide if one anticancer drug is for advanced cancer?
|
|
8
|
375
|
November 20, 2024
|
|
活性炭成为亚硝酸根来源的风险如何控制？
|
|
3
|
152
|
November 16, 2024
|
|
4-(nitroso(vinyl)amino)butanoic acid from Kollidon?
|
|
7
|
293
|
August 29, 2024
|
|
Health Canada: Nitrosamine impurities Update July 26, 2024
|
|
14
|
1083
|
August 26, 2024
|
|
DMF in API, specification limit in formulation
|
|
5
|
712
|
August 26, 2024
|
|
Control limit of Nitrosamines and N-nitroso compounds
|
|
2
|
411
|
July 8, 2024
|
|
On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes -Pub
|
|
0
|
186
|
June 13, 2024
|
|
🇰🇷 Case study on the Occurrence of Impurities in Pharmaceuticals (Focusing on NDMA Cases)
|
|
0
|
289
|
May 31, 2024
|
|
🇪🇺 EDQM - top 10 deficiencies observed in new CEP applications
|
|
0
|
925
|
March 14, 2024
|
|
🇺🇸 FDA CDER Generic Drug Forum (GDF) 2024
|
|
5
|
1366
|
April 14, 2024
|
|
Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub
|
|
0
|
1155
|
June 6, 2023
|
|
Nitrosamine Risk Assessments in Oligonucleotides
|
|
2
|
644
|
August 10, 2023
|